Genoloam Selected by EDGC as the Official Supervising Partner for Liquid Biopsy Research

February 15, 2022

EDGC is a world-class global healthcare company that develops leading cutting-edge technology for genome sequencing through fusion of personal medical and genetic data. As the global leader of genome business, EDGC has worked on innovative projects with the most influential BT and IT companies in the world such as Illumina and Microsoft. In addition, EDGC is participating as the only Asian partner of the Global Screening Array Consortium, in which only 12 other global leading companies participate in.

Their latest development in Liquid Biopsy for Early Diagnosis of Cancer, Monitoring Cancer, Companion Diagnostics and Organ Transplant Rejection Monitoring without the need for Tissue Biopsy is another successful step forwards in ultra-precision medicine field. EDGC’s Liquid Biopsy technology is state-of-the-art personalized precision medical service that can be used for early diagnosis (screening), recurrence of cancer (monitoring), and anticancer drug effect (companion diagnostics) using Circulating Tumor Cell (CTC), a cfDNA derived from cancer cells. The cancer cell-derived cfDNA is analyzed through NGS technology and bioinformatics to see if there is a mutation that causes cancer, and whether it can be effective against the anticancer drug. With this technology, EDGC can analyze more than tens of thousands of methylation markers and trace amounts of cfDNA with high sensitivity, for example, the current detection rate for breast cancer, colorectal cancer and lung cancer through this technology has surpassed 90% in sensitivity and specificity. In March 2020, EDGC liquid biopsy technology was approved for good manufacturing practice (GMP) in Korea and now, EDGC is preparing to launch their commercial cancer test solution in the EU market.

For this purpose, EDGC has officially chosen GENOLOAM as their representative supervising partner in the EU market. Together, we are on track to begin liquid biopsy clinical research in Finland, where we will be partnering with leading university hospitals and cutting-edge medical institutions in Finland and other countries in the Scandinavian region. Under GENOLOAM’s industry lead and expertise, we aim to complete the clinical research by early next year and launch the commercial cancer test solution for the EU market.

EDGC’s liquid biopsy technology is expected to disrupt cancer detection and diagnosis, and GENOLOAM is proud to be at the forefront of such exciting developments and help revolutionize the healthcare market through personalized precision medicine.

If you want to learn more about our current and upcoming products and services, contact us today.